PSS15 - BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE

Abstract

To assess the budget impact of increasing the use of apremilast in the management of adult patients with moderate-to-severe chronic plaque psoriasis (PsO), who have failed to respond to or have a contradiction to, or are intolerant to other systemic therapy from a Greek payer perspective. A 5-year (2018-2022) budget impact model was developed to estimate healthcare costs for adults with moderate-to-severe plaque PsO. Target population was defined based on epidemiological data, obtained from a local panel of experts and the literature. The population was divided into three categories; patients receiving conventional systemic therapy eligible to receive treatment with biologics or apremilast, patients currently treated with biologics or apremilast (switchers), and newly diagnosed patients eligible to receive treatment with biologics or apremilast (incidents). The analysis included all relevant currently reimbursed biologics (adalimumab, etanercept, infliximab, ustekinumab, secukinumab) and apremilast. Biosimilars for etanercept and infliximab were also included in the model. IMS (2017) prescription data were used for building up the market shares. Following a payer perspective, direct costs relating to drug acquisition and administration were considered (€, 2018). A total of 10,777 patients were estimated to receive biologics or apremilast in the first model year. Increased penetration of apremilast resulted in an estimated reduction of the total budget by 28.6%, leading to cost-savings of €31,606,416 over 5 years (€527,470,278 vs €495,863,863). Total costs per patient decreased by €2,374 over the same time period. The model yielded average annual cost-savings of 5.7% compared to the current treatment scenario. The sensitivity analyses confirmed the robustness of the model results. Increased use of apremilast for the treatment of moderate-to-severe plaque PsO represents a cost-saving strategy in the Greek healthcare setting.